New vaccine strategy may better shield vulnerable patients from pneumonia
NCT ID NCT03069703
First seen Nov 20, 2025 · Last updated Jun 16, 2026 · Updated 27 times
Summary
This study tested whether giving a stronger or extra dose of the pneumococcal vaccine could improve immune protection in 96 adults with ANCA-associated vasculitis who are taking rituximab. Participants received either the standard vaccine schedule or one of two reinforced schedules. The goal was to see if the stronger strategies produce a better immune response without increasing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE PNEUMOCOCCAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pôle de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques " Hôpital Cochin, Assistance Publique-Hôpitaux de Paris
Paris, Paris, 75014, France
Conditions
Explore the condition pages connected to this study.